2 nominees · 4 ballot items.
Four proposals: election of two Class III directors, advisory approval of named executive officer compensation (say-on-pay), advisory vote on the frequency of future say‑on‑pay votes, and ratification of Ernst & Young LLP as the Company’s independent registered public accounting firm for 2026.
Election of two Class III directors — Michael Landsittel and Cameron Turtle, D.Phil — to serve three‑year terms expiring at the 2029 annual meeting.
Non‑binding advisory “say‑on‑pay” vote to approve the compensation paid to the company’s named executive officers as disclosed in the proxy statement.
This proposal asks shareholders to cast a non‑binding advisory vote to approve the company’s named executive officer compensation as disclosed in the proxy. Management is pursuing this approval as a routine governance practice (a “say‑on‑pay” vote) required by Section 14A and to obtain shareholder feedback on its compensation policies, which the Compensation Committee views as aligned with company strategy and retention objectives. The compensation program described emphasizes a mix of base salary, cash bonuses (including retention bonuses tied to transactions or milestones), and equity incentives to align executives’ interests with long‑term shareholder value. The context includes recent retention payments and separation arrangements disclosed for certain executives, as well as accelerated equity vesting in certain severance events, which could influence shareholder sentiment about pay-for-performance alignment. The board recommends a FOR vote, stating that the Compensation Committee believes the policies and practices effectively implement the company’s compensation philosophy and achieve program goals; it also notes that the advisory vote is not binding but will be considered in future decisions. Key governance considerations for an analyst include the prominence of retention and separation payments (including recent acceleration of equity upon a CEO separation), the company’s status as a smaller reporting company (which affects disclosure), and the degree to which equity awards drive realized pay and link to TSR. Given these factors, an analyst should weigh whether disclosed pay practices appropriately tie payouts to long‑term performance, the transparency of severance/retention arrangements, and the company’s rationale for its compensation design when evaluating the merits of the Board’s recommendation.
Non‑binding advisory choice among one year, two years, or three years for the frequency of future say‑on‑pay votes; the Board recommends one year.
This proposal asks shareholders to indicate, on a non‑binding basis, whether future advisory votes on executive compensation should be held every one, two or three years. Management supports an annual frequency and frames the vote as a mechanism to obtain more frequent and direct shareholder input on compensation practices. The Board’s recommendation for annual voting is grounded in considerations of transparency and accountability: more frequent votes allow shareholders to respond quickly to material changes in pay practices or corporate performance and give the Compensation Committee more immediate feedback. From an analyst perspective, the issues to consider include tradeoffs between responsiveness and administrative burden—annual votes increase engagement opportunities but can encourage short‑term focus—versus multi‑year votes that provide a longer runway for multi‑year incentive plans. Company‑specific context includes recent management and organizational changes (CEO transition and retention payments) and evolving compensation arrangements, which could justify more frequent shareholder feedback in the near term. The vote is non‑binding; the Board will consider the plurality outcome and may adopt the option receiving the most votes. Analysts should assess whether annual voting will meaningfully improve governance oversight of pay or simply increase proxy activity without changing substantive compensation design.
Ratify the Audit Committee’s appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Fairmount Funds Management LLC | 14.2% | 8,713,000 | $226M |
| 2 | FMR LLC | 10.6% | 6,520,036 | $169M |
| 3 | Avoro Capital Advisors LLC | 6.1% | 3,783,000 | $98M |
| 4 | Venrock Adviser, LLC | 5.9% | 3,603,595 | $93M |
| 5 | FMR LLC | 4.0% | 2,441,937 | $63M |
| 6 | FCPM III SERVICES B.V. | 4.0% | 2,441,000 | $63M |
| 7 | RA CAPITAL MANAGEMENT, L.P. | 3.9% | 2,399,310 | $62M |
| 8 | JANUS HENDERSON GROUP PLC | 3.8% | 2,362,696 | $61M |
| 9 | VIKING GLOBAL INVESTORS LP | 3.8% | 2,311,082 | $60M |
| 10 | Bellevue Group AG | 3.7% | 2,298,000 | $60M |
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.